Moderna (MRNA) Guides FY23 Covid-19 Vax Revenue of $6B-$8B

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. RTX
6. COF
7. SMCI
8. BRZE
9. TSLA
10. GOOGL

Go back to Moderna (MRNA) Guides FY23 Covid-19 Vax Revenue of $6B-$8B

Moderna Reports Second Quarter 2023 Financial Results and Provides Business Updates

August 3, 2023 6:31 AM EDT

Second quarter 2023 revenues of $0.3 billion; net loss of $1.4 billion and loss per share of $3.62

Company expecting 2023 COVID-19 vaccine sales of $6 billion to $8 billion, dependent on U.S. vaccination rates

Company submitted its investigational RSV vaccine to several regulators globally ahead of potential 2024 launch

With its partner Merck, the Company began Phase 3 trial of mRNA-4157, its individualized neoantigen therapy (INT), in combination with Keytruda, for high-risk melanoma

CAMBRIDGE, MA / ACCESSWIRE / August 3, 2023 /... More